Jubilant Pharmova Management
Management criteria checks 1/4
Jubilant Pharmova's CEO is Priyavrat Bhartia, appointed in Jun 2023, has a tenure of 1.42 years. total yearly compensation is ₹67.47M, comprised of 37.1% salary and 62.9% bonuses, including company stock and options. directly owns 0.88% of the company’s shares, worth ₹1.58B. The average tenure of the management team and the board of directors is 1.8 years and 6.8 years respectively.
Key information
Priyavrat Bhartia
Chief executive officer
₹67.5m
Total compensation
| CEO salary percentage | 37.1% |
| CEO tenure | 1.4yrs |
| CEO ownership | 0.9% |
| Management average tenure | 1.8yrs |
| Board average tenure | 6.8yrs |
Recent management updates
Recent updates
Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Nov 15
A Look At The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Oct 27Jubilant Pharmova Limited (NSE:JUBLPHARMA) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Aug 24Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Jul 13Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Mar 14Jubilant Pharmova Limited (NSE:JUBLPHARMA) Shares Fly 27% But Investors Aren't Buying For Growth
Dec 23These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Dec 02These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Jul 26Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
May 11Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Dec 10Jubilant Pharmova (NSE:JUBLPHARMA) Has Announced A Dividend Of ₹5.00
Aug 01Does Jubilant Pharmova (NSE:JUBLPHARMA) Have A Healthy Balance Sheet?
Jun 15Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Mar 22Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Feb 15Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Dec 20Here's Why It's Unlikely That Jubilant Pharmova Limited's (NSE:JUBLPHARMA) CEO Will See A Pay Rise This Year
Sep 15Here's Why Jubilant Pharmova (NSE:JUBLPHARMA) Can Manage Its Debt Responsibly
Aug 21Time To Worry? Analysts Are Downgrading Their Jubilant Pharmova Limited (NSE:JUBLPHARMA) Outlook
Jun 08An Intrinsic Calculation For Jubilant Pharmova Limited (NSE:JUBLPHARMA) Suggests It's 39% Undervalued
May 25Analysts Just Made A Major Revision To Their Jubilant Pharmova Limited (NSE:JUBILANT) Revenue Forecasts
Feb 10Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBILANT)
Feb 08
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹6b |
| Jun 30 2024 | n/a | n/a | ₹6b |
| Mar 31 2024 | ₹67m | ₹25m | ₹771m |
Compensation vs Market: Priyavrat's total compensation ($USD798.47K) is above average for companies of similar size in the Indian market ($USD502.40K).
Compensation vs Earnings: Insufficient data to compare Priyavrat's compensation with company performance.
CEO
Priyavrat Bhartia (48 yo)
1.4yrs
Tenure
₹67,466,997
Compensation
Mr. Priyavrat Bhartia, MBA, is the Non-Executive Chairman at Digicontent Limited and has been its Non-Executive Director since August 14, 2017. He has been Non-Executive Director of Hindustan Media Venture...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Director | 1.4yrs | ₹67.47m | 0.88% ₹ 1.6b | |
| Joint MD & Director | 1.4yrs | ₹67.47m | no data | |
| Group CFO & Whole-Time Director | 1.5yrs | ₹44.78m | no data | |
| Executive VP of Group Accounts | no data | no data | no data | |
| Group Chief Digital & Information Officer | no data | ₹16.53m | no data | |
| Head of Investor Relations | no data | no data | no data | |
| Executive VP & Head of Legal | 10yrs | ₹3.34m | no data | |
| Company Secretary & Compliance Officer | 2.3yrs | ₹6.86m | no data | |
| Group Chief Human Resources Officer | 1.8yrs | no data | no data | |
| Advisor | 4.7yrs | ₹67.29m | no data | |
| Senior Vice President of Corporate Affairs | no data | no data | no data | |
| President of Life Science Chemicals | no data | ₹19.34m | no data |
1.8yrs
Average Tenure
55yo
Average Age
Experienced Management: JUBLPHARMA's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Director | 7.5yrs | ₹67.47m | 0.88% ₹ 1.6b | |
| Joint MD & Director | 7.5yrs | ₹67.47m | no data | |
| Group CFO & Whole-Time Director | 3.6yrs | ₹44.78m | no data | |
| Additional Director & Whole-time Director | less than a year | no data | no data | |
| Chairman | 46.4yrs | no data | 0.085% ₹ 151.8m | |
| Independent Non-Executive Director | 7.5yrs | ₹2.59m | no data | |
| Independent Non-Executive Director | 6.1yrs | ₹2.01m | 0.0013% ₹ 2.3m | |
| Independent Director | less than a year | no data | no data | |
| Co-Chairman | 41yrs | ₹124.06m | 0.23% ₹ 419.7m | |
| Independent Director | less than a year | no data | no data | |
| Independent Non-Executive Director | 7.5yrs | ₹2.53m | no data | |
| Additional Independent Non-Executive Director | 1.7yrs | ₹2.23m | no data |
6.8yrs
Average Tenure
66yo
Average Age
Experienced Board: JUBLPHARMA's board of directors are considered experienced (6.8 years average tenure).